Noci Darlene 的 Form 4 申報
Nuvalent, Inc.（NUVL），2026/7/15 申報
- 申報編號
- 0001193125-26-305072
- 申報時間
- 2026/7/15 18:57 ET
- 交易日
- 2026/7/15
- 申報延遲
- 當天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 4 筆非衍生性交易、8 筆衍生性交易。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Noci DarleneCIK 0001862148 | 高階主管（發展長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/15 | Class A Common Stock | U少見代碼處分 | −17,017 | $124.00F1,F2 | −$2,110,108 | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock - Restricted Stock Units | D交回公司處分 | −41,100 | –F4 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock - Performance Stock Units | A公司授予取得 | +14,350 | $0.00 | $0 | 14,350 | 直接 | |
| 2026/7/15 | Class A Common Stock - Performance Stock Units | D交回公司處分 | −14,350 | –F6 | – | 0 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −216 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −6,091 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −15,112 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −21,259 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −81,329 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −33,646 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −37,500 | –F7 | – | 0 | 直接 | |
| 2026/7/15 | Class A Common Stock | D交回公司處分 | −17,500 | –F7 | – | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.
表 I 有 1 筆交易的價格引用這則附註。
- F2
(Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Pursuant to the Merger Agreement, each restricted stock unit that was subject to time- and performance-based vesting (a "Company PSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company PSU immediately prior to the effective time of the Merger, assuming applicable performance goals were achieved in full, and (y) the Offer Price.
表 I 有 1 筆交易的價格引用這則附註。
- F7
Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.
表 II 有 8 筆交易的價格引用這則附註。